News

    Aptahem receives patent protection in Japan for patent family 2

    2022-02-16

    Aptahem AB (publ) announces today that the company has received patent protection in Japan for patent family 2 from the Japanese Patent Office (JPO). With JPO’s approval of patent application 2020-519806, the protection of the company’s drug candidate Apta-1...

    Read More

    BioStock article: Aptahem recruits to key positions before clinical studies

    2022-02-04

    BioStock published an article on 4 February 2022 about Aptahem, which can be read in full below. Aptahem has recently recruited to fill three key positions ahead of the phase I studies planned with sepsis candidate Apta-1. Karin Aschan...

    Read More

    Aptahem appoints CMC Director

    2022-01-31

    Aptahem (publ) announces today that Thomas Rupp has been appointed CMC Director in the company. Thomas has worked with Aptahem for several year in the role as aptamer expert, but he will now also take on the role as...

    Read More

    Aptahem appoints new COO

    2022-01-13

    Aptahem (publ) announces today that Maria Ekblad has been appointed new Chief Operating Officer (COO) in the company as of 14 January 2022. Maria has long and solid experience from the pharmaceutical industry where she has held senior management...

    Read More

    Aptahem signs start up agreement with international clinical CRO for phase 1 studies with Apta-1

    2022-01-07

    Aptahem (publ) announces today that the company has signed an agreement to initiate activities (Start Up Agreement, SUA) with the clinical contract research organization (CRO) The Centre for Human Drug Research (CHDR) in the Netherlands to prepare the upcoming...

    Read More

    Aptahem’s patent family 2 in Europe has been finalized by validation in the 11 countries where applied

    2021-12-02

    Aptahem AB (publ) announces today that in all countries in Europe where the company has applied for patent protection now have validated and approved the patent family 2. The patent has been published with patent number 3691655. With these...

    Read More

    BioStock article: Aptahem’s new research findings explained

    2021-12-02

    BioStock published an article on 2 December 2021 about Aptahem, which can be read in full below. Aptahem’s collaboration with Örebro University recently led to a research breakthrough regarding a newfound pharmacological mechanism behind Aptahem’s sepsis treatment Apta-1. BioStock...

    Read More

    Aptahem has started the production of GMP certified Apta-1 for clinical trials

    2021-11-03

    Aptahem can today announce that the production of Good Manufacturing Practice (GMP) manufacturing of the drug candidate Apta-1 has started at the collaboration partner LGC Biotechnologies’ facilities in the USA, with planned delivery date in early 2022. The GMP...

    Read More

    Aptahem announces positive biological effect in a Corona virus-induced acute lung injury model treated with Apta-1

    2021-10-29

    Aptahem can today announce that in a Corona virus challenge induced Acute Lung Injury model studies with Apta-1 treatment shows strong evidence in maintaining systemic circulation, protection of vital organs, regulation of crucial cytokines and preventing hemolysis. Research commissioned...

    Read More

    BioStock article: Eight CEOs on their expectations at BIO-Europe

    2021-10-25

    It is time for 2021’s edition of the largest partnering meeting in the life science space – BIO-Europe. This week, representatives from nearly 1,500 companies will gather to establish new contacts as well as continue initiated discussions with potential...

    Read More